Upfront Briefing
Fosun Pharma paid US$60M to option AriBio's Phase 3 oral Alzheimer's asset AR1001 globally (up to US$180M more on exercise), opening the day's deal flow with a sharp price signal in CNS. Ipsen used SCALE to launch corabotase (IPN10200) as the first molecule in a newly designated WHO/USAN class — recombinant neuroinhibitors (RNI™) — backed by LANTIC Phase II data showing a longer-lasting profile than Dysport, putting the multi-billion-dollar neurotoxin aesthetics market in play. And Altimmune's Q1 update set up a twin catalyst window: PERFORMA Phase 3 MASH start in 2H26 and RECLAIM Phase 2 AUD topline in Q3 2026, with US$535M cash funding pemvidutide through to 2029.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,444.2 |
+0.6% |
+8.9% |
| Nasdaq 100 |
29,366.9 |
+1.0% |
+19.0% |
| Russell 2000 |
2,843.9 |
0.0% |
+8.7% |
| Healthcare (XLV) |
146.7 |
+0.6% |
(5.6%) |
| Biotech (XBI) |
135.9 |
+0.7% |
+10.3% |
| Nasdaq Biotech (NBI) |
6,029.0 |
+0.5% |
+2.9% |
| Clinical Trials (BBC) |
45.0 |
+0.9% |
+11.6% |
|
- S&P 500 and Nasdaq 100 closed at fresh record highs as a tech-led bid (Nvidia +2%, semis SMH +2%) shrugged off a sharply hotter April PPI print (+1.4% MoM; +6.0% YoY vs. +0.5%/+4.9% consensus) — the biggest monthly wholesale jump since March 2022.
- Biotech outperformed quietly: XBI +0.7%, NBI +0.5%, BBC +0.9% — a constructive tone into Thursday's deal flow even with PPI complicating the rate-cut path; XLV +0.6% kept defensives bid alongside tech.
- Market data: U.S. close Wed 13-May-2026.
The Big 3
|
1
|
Fosun Pharma, AriBio sign global option deal for AR1001
|
- Fosun Pharma paid US$60M upfront to option AriBio's once-daily oral PDE5 inhibitor AR1001 (mirodenafil) in the US, EU and Japan; up to US$180M in additional upfront and regulatory milestones is due on option exercise, with sales milestones triggered above US$2.5B in annual net product sales. Extends Fosun's prior Greater China/ASEAN rights to a global footprint ahead of the Phase 3 POLARIS-AD readout.
- Why it matters: An option (rather than outright license) keeps Fosun's capital at risk small until POLARIS-AD reads out, while still locking in pre-agreed exercise economics. For AriBio holders, the deal puts a public floor on AR1001's global value and de-risks the next financing window; for the CNS sector, it is another datapoint that big-pharma partners are willing to pay meaningful option premia for late-stage Alzheimer's assets despite the disease-modifying class's mixed clinical record.
- Source: PR; Fierce Biotech
|
|
2
|
Ipsen launches corabotase as first-in-class RNI at SCALE
|
- Ipsen used the SCALE Symposium to unveil corabotase (IPN10200) as the first molecule in a newly designated drug class — recombinant neuroinhibitor (RNI™) — recognised by both the WHO and USAN. The launch is backed by Phase II LANTIC data (n=183, glabellar lines): rapid onset at Week 4 in line with Dysport, but a clinically significant response sustained through Weeks 24 and 36 vs both placebo and Dysport, with no safety concerns at any dose. Pivotal Phase III is gated to start.
- Why it matters: The neurotoxin aesthetics market — ~US$7B annually and effectively a Botox (AbbVie) / Dysport (Ipsen) / Xeomin (Merz) oligopoly — is built on a 3–4-month re-dose cycle. A clinically meaningful duration advantage at Week 36 directly challenges that re-dose cadence, the economic engine of the category. For Ipsen, corabotase reframes the aesthetics franchise from defending Dysport against generics to leading a new class; for AbbVie, it puts the strongest pipeline threat to Botox in years on the radar ahead of Phase III. The WHO/USAN class designation also signals regulators are willing to differentiate recombinant from biologic-derived neuromodulators — a label-and-pricing tailwind.
-
Source:
PR; LANTIC Phase II
|
| 3 | Altimmune sets twin pemvidutide catalysts in MASH and AUD |
-
Altimmune (ALT) Q1 update confirms PERFORMA Phase 3 in MASH starts in 2H26 (52-week readout in 2029; pemvidutide carries FDA Breakthrough Therapy Designation; trial design aligned with FDA + EMA) and RECLAIM Phase 2 in AUD topline reads out in Q3 2026 (24-week, ~100 patients, enrolment completed Nov-25, ahead of schedule). Cash US$535M as of 30-Apr-26 (post equity raise) funds operations through the PERFORMA 52-week readout. Pemvidutide is a balanced 1:1 GLP-1 / glucagon dual agonist developed in MASH, AUD and ALD.
-
Why it matters:
Two distinct catalysts inside the next five months — RECLAIM topline in Q3 2026 and PERFORMA initiation in 2H26 — keep ALT in active news flow while a US$535M cash position effectively removes dilution risk through the 2029 pivotal. The MASH set-up has sector implications: pemvidutide's glucagon arm positions it as a differentiated, lean-mass-sparing alternative to GLP-1 mono-agonists, making it the cleanest large-cap-quality late-stage MASH bet outside Madrigal's Rezdiffra and the Lilly/Novo dual agonists. AUD provides the optionality leg — a positive RECLAIM read opens a category with no approved injectable therapy and a ~30M US adult patient pool.
-
Source:
BioSpace; Seeking Alpha
|
Everything Else that broke
- Oruka reports Q1 results with EVERLAST-A data update. — PR
- Vivani reports Q1, keeps semaglutide implant on track. — PR
- Journey Medical reports Q1 results with 21% revenue growth. — PR
- vTv says Phase 3 CATT1 enrollment stays on track. — PR
- Equillium keeps EQ504 Phase 1 start on track. — PR
- Propanc implements reverse split to support Nasdaq listing. — PR
- Reviva (RVPH) reports Q1 2026 with brilaroxazine Phase 3 timing and IP-runway update. — PR
- BioSpace: biotech hiring up year over year, layoffs still high. — BioSpace
- GenesisCare, SeeTreat expand monitoring in Australia. — PR
- Abu Dhabi Department of Health and Fred Hutchinson Cancer Center sign MOU on multi-omics, AI and personalised prevention. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Fosun Pharma signed a global exclusive option agreement with AriBio for AR1001 (oral PDE5 inhibitor) in Alzheimer's: US$60M option fee upfront; up to US$180M in additional upfront + regulatory milestones on exercise; sales milestones triggered above US$2.5B in annual net sales. Covers US, EU and Japan (extends Fosun's existing China/ASEAN rights). — Fierce Biotech; PR
VC / Private Financings
- NinaMED (Australia; OAB neuromodulation; spun out alongside EBT Medical license) — US$13.75M (A$19M) financing led by SPRIM Global Investments, joined by SV Health Investors. — PR
IPOs / Follow-Ons
- No notable biotech IPOs or follow-ons surfaced inside the last 24 hours. — BioBucks
Academic Corner - Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial. — NEJM
- A Phase 3 Trial of Brepocitinib in Dermatomyositis. — NEJM
- Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models. — Nature Biotech
- Trends in the landscape of clinical trials of innovative drugs in China since 2015. — Nature RDD
|
